-+ 0.00%
-+ 0.00%
-+ 0.00%

LIMINATUS PHARMA ENGAGES SYNEX AS CONTRACT RESEARCH ORGANIZATION TO SUPPORT PHASE 1/2A CLINICAL DEVELOPMENT OF CD19XCD22 BIVALENT CAR-T THERAPY

路透·08/24/2026 12:00:43

登录查看新闻详情